Table 1 Patients characteristics and main study results according to the 2 study groups (unfavourable and favourable)
Whole group | Unfavourable | Favourable | p value | |
|---|---|---|---|---|
(n = 46) | (n = 29) | (n = 17) | ||
Age (range) | 67 (36–81) | 66 (36–79) | 67 (38–81) | ns |
Sex | ||||
Males | 30 (65%) | 21 (72%) | 9 (53%) | ns |
Females | 16 (35%) | 8 (28%) | 7 (47%) | ns |
ECOG PS | ||||
0-1 | 29 (63%) | 18 (62%) | 11 (65%) | ns |
2-3 | 17 (47%) | 11 (38%) | 6 (35%) | ns |
Metastatic sites | ||||
1 | 7 (15%) | 5 (17%) | 2 (12%) | ns |
≥ 2 | 39 (85%) | 24 (83%) | 15 (88%) | ns |
Previous lines of treatment | ||||
1 | 10 (22%) | 6 (21%) | 4 (9%) | ns |
≥ 2 | 36 (78%) | 23 (89%) | 15 (88%) | ns |
Treatment | ||||
FOLFIRI/Cet | 9 (19%) | 6 (21%) | 3 (23%) | ns |
Irinotecan/Cet | 37 (81%) | 23 (79%) | 14 (77%) | ns |
Response rate | ||||
PR | 13 (26%) | 2 (7%) | 11 (65%) | 0.007 |
SD | 6 (16%) | 3 (10%) | 3 (18%) | 0.8 |
DCR (PR + SD) | 19 (41%) | 5 (17%) | 14 (82%) | 0.0001 |
PD | 27 (59%) | 24 (83%) | 3 (18%) | 0.0001 |
Survival | ||||
PFS(months) | 3.3 | 3 | 8 | < 0.0001 |
OS (months) | 11 | 6 | 15 | < 0.0001 |